NASDAQ:GLTO

Galecto Stock Forecast, Price & News

$4.29

-0.07 (-1.61 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.27

▼

$4.35

50-Day Range

$4.16

▼

$8.00

52-Week Range

$4.03

▼

$17.99

Volume33,080 shs

Average Volume283,348 shs

Market Capitalization$108.37 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive GLTO News and Ratings via Email

Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter.

About Galecto

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Galecto, Inc. (NASDAQ:GLTO) Short Interest Update
July 30, 2021 | americanbankingnews.com

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
July 28, 2021 | finance.yahoo.com

Galecto, Inc. (NASDAQ:GLTO) Expected to Post Earnings of -$0.54 Per Share
July 23, 2021 | americanbankingnews.com

Comparing Tempest Therapeutics (NASDAQ:TPST) and Galecto (NASDAQ:GLTO)
July 22, 2021 | americanbankingnews.com

Short Interest in Galecto, Inc. (NASDAQ:GLTO) Rises By 57.2%
July 17, 2021 | americanbankingnews.com

Insider Selling: Galecto, Inc. (NASDAQ:GLTO) Insider Sells 83,372 Shares of Stock
July 15, 2021 | americanbankingnews.com

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis
July 13, 2021 | finance.yahoo.com

Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs
June 22, 2021 | finance.yahoo.com

Galecto’s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
June 22, 2021 | finance.yahoo.com

Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times
June 18, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLTO
Previous Symbol
CUSIPN/A
CIKN/A
Webgalecto.com
Phone45 70 70 52 10
Employees28
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.55 per share
Price / Book0.65

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares25,260,000
Market Cap$108.37 million
Next Earnings Date8/3/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.33 out of 5 stars

Medical Sector

241st out of 2,220 stocks

Pharmaceutical Preparations Industry

114th out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
Galecto has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, Galecto has a forecasted upside of 226.3% from its current price of $4.29.
Amount of Analyst Coverage
Galecto has received no research coverage in the past 90 days.

5.0 Community Rank

Outperform Votes
Galecto has received 11 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Galecto has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Galecto has received 78.57% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Galecto and other stocks. Vote “Outperform” if you believe GLTO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLTO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Galecto does not currently pay a dividend.
Dividend Growth
Galecto does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galecto insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,330.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.10% of the stock of Galecto is held by insiders.
Percentage Held by Institutions
54.21% of the stock of Galecto is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Galecto are expected to decrease in the coming year, from ($2.27) to ($2.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galecto is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galecto is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galecto has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Galecto (NASDAQ:GLTO) Frequently Asked Questions

Is Galecto a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galecto stock.
View analyst ratings for Galecto or view top-rated stocks.

What stocks does MarketBeat like better than Galecto?

Wall Street analysts have given Galecto a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galecto wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Galecto?

Galecto saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 251,700 shares, a decline of 40.6% from the June 30th total of 423,600 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.7% of the shares of the company are sold short.
View Galecto's Short Interest.

When is Galecto's next earnings date?

Galecto is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Galecto.

How were Galecto's earnings last quarter?

Galecto, Inc. (NASDAQ:GLTO) issued its earnings results on Tuesday, May, 4th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.07.
View Galecto's earnings history.

What price target have analysts set for GLTO?

3 analysts have issued 1 year price targets for Galecto's stock. Their forecasts range from $12.00 to $16.00. On average, they expect Galecto's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 226.3% from the stock's current price.
View analysts' price targets for Galecto or view top-rated stocks among Wall Street analysts.

Who are Galecto's key executives?

Galecto's management team includes the following people:

Dr. Hans T. Schambye, Co-Founder, Pres, CEO & Director (Age 55, Pay $644.98k)
Mr. Anders Pedersen, Chief Operating Officer (Age 61, Pay $449.66k)
Prof. Bertil Lindmark M.D., Ph.D., Chief Medical Officer (Age 66, Pay $602.63k)
Mr. Ulf J. Nilsson, Co-Founder
Dr. Hakon Leffler, Co-Founder
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPF
Mr. Jonathan P. Freve CPA, CPA, Chief Financial Officer (Age 43)
Mr. Garrett Winslow, Sr. VP & Gen. Counsel (Age 42)

Who are some of Galecto's key competitors?

Some companies that are related to Galecto include PLx Pharma (PLXP), ANI Pharmaceuticals (ANIP), Magenta Therapeutics (MGTA), Kindred Biosciences (KIN), Athenex (ATNX), Bolt Biotherapeutics (BOLT), Forte Biosciences (FBRX), Spero Therapeutics (SPRO), Akebia Therapeutics (AKBA), Inozyme Pharma (INZY), TherapeuticsMD (TXMD), Molecular Templates (MTEM), Selecta Biosciences (SELB), Viracta Therapeutics (VIRX) and Geron (GERN).
View all of GLTO's competitors.

When did Galecto IPO?

(GLTO) raised $86 million in an initial public offering on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager.

What is Galecto's stock symbol?

Galecto trades on the NASDAQ under the ticker symbol "GLTO."

Who are Galecto's major shareholders?

Galecto's stock is owned by a number of retail and institutional investors. Top institutional investors include Asymmetry Capital Management L.P. (0.24%). Company insiders that own Galecto stock include Bertil Lindmark, Hans T Schambye and Jonathan Freve.
View institutional ownership trends for Galecto.

Which major investors are selling Galecto stock?

GLTO stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P..
View insider buying and selling activity for Galecto or view top insider-selling stocks.

How do I buy shares of Galecto?

Shares of GLTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galecto's stock price today?

One share of GLTO stock can currently be purchased for approximately $4.29.

How much money does Galecto make?

Galecto has a market capitalization of $108.37 million. The company earns $-34,840,000.00 in net income (profit) each year or ($7.62) on an earnings per share basis.

How many employees does Galecto have?

Galecto employs 28 workers across the globe.

What is Galecto's official website?

The official website for Galecto is galecto.com.

Where are Galecto's headquarters?

Galecto is headquartered at GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200.

How can I contact Galecto?

Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The company can be reached via phone at 45 70 70 52 10.

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here